22 September 2026

Oncoinvent ASA – Key information relating to subsequent offering

Reference is made to the stock exchange announcement made by Oncoinvent ASA (the “Company“) on 22 September 2026 regarding the allocation of 1,531,000 new shares in the Company in a private placement (the “Private Placement“) and 119,000 new shares in a retail offering, and a potential subsequent repair offering of up to 200,000 new shares at the same subscription price as in the Private Placement and the retail offering (the “Subsequent Offering“). The Subsequent Offering will, subject to applicable securities law, be directed towards existing shareholders in the Company as of 22 September 2026, as registered in the Company’s register of shareholders with Euronext Securities Oslo on 24 September 2026, who (i) were not allocated shares in the Private Placement, and (ii) are not resident in a jurisdiction where such offering would be unlawful or, would (in jurisdictions other than Norway) require a prospectus, filing registration or similar action.

The following key information is provided with respect to the Subsequent Offering:

Date on which the terms and conditions of the Subsequent Offering were announced: 22 September 2026

Last day including right: 22 September 2026

Ex-date: 23 September 2026

Record date: 24 September 2026

Date of approval: 22 September 2026 (subject to final approval by the board of launch of the Subsequent Offering)   

Maximum number of new shares: 200,000

Subscription price: NOK 90 per share

Shall the rights be listed: No

Other information: The Subsequent Offering is subject to, inter alia, completion of the Private Placement, approval by the board of directors, registration of the board authorization to increase the share capital granted by the annual general meeting held on 20 May 2026 (under agenda item 13.4), and the publication of a prospectus. Whether or not the Subsequent Offering will ultimately take place, will depend inter alia on the development of the price of the shares in the Company after completion of the Private Placement, and the Company reserves the right in its sole discretion to not conduct or to cancel the Subsequent Offering.

This information is published in accordance with the requirements of the Continuing Obligations for Euronext Oslo Børs.

For further information, please contact:

Oystein Soug, Chief Executive Officer
Email: IR@oncoinvent.com



Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.

Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997

close

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.

close